NGL Fine Chem Quarterly Results for Trading Insights
In Mar 2026, NGL Fine Chem (NGLFINE) reported revenue ₹152 Cr and net profit ₹14 Cr — revenue +61.7% YoY. For annual financials, live price and key ratios, visit NGLFINE stock price BSE.
NGLFINE Quarterly Results — Revenue, Profit & EPS Highlights
NGL Fine Chem latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore NGL Fine Chem stock price data download to track price trends across different timeframes.
- Revenue of ₹152 Cr in Mar 2026 (+24.6% vs Sept 2025, +61.7% vs Mar 2025)
- Net Profit of ₹14 Cr in Mar 2026 (+40.0% vs Sept 2025, +1300.0% vs Mar 2025)
- EBITDA of ₹24 Cr in Mar 2026 (+26.3% vs Sept 2025)
- Operating Margin of 14.0% in Mar 2026 (+0.0pp vs Sept 2025)
- Earnings Per Share of ₹21.83 in Mar 2026 (+40.1% vs Sept 2025)
NGL Fine Chem Quarterly Results — Revenue, EBITDA, Net Profit & EPS
NGLFINE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 152 | 122 | 94 | 111 | 132 | 24.6% | 61.7% |
| Net Profit (₹ Cr) | 14 | 10 | 1 | 9 | 16 | - | - |
| EBITDA (₹ Cr) | 24 | 19 | 5 | 17 | 27 | - | - |
| EPS (₹) | 21.83 | 15.58 | 0.88 | 14.96 | 25.40 | - | - |
| Operating Margin (%) | 14.0% | 14.0% | 7.0% | 11.0% | 18.0% | - | - |
NGLFINE Share Price Trend — 1-Year Movement Across Quarterly Results
NGL Fine Chem 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse NGL Fine Chem financial data for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
NGLFINE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
NGL Fine Chem latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹469,405.89 Cr | 1941.1 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 171.8 |
|
Divis Laboratories
Mar 2026 |
₹194,269.91 Cr | 7248.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 256.0 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹191,454.40 Cr | 4961.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.1 |
|
Zydus Life Science
Mar 2026 |
₹115,616.29 Cr | 1108.7 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 87.6 |
|
Cipla
Mar 2026 |
₹114,318.19 Cr | 1410.6 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 205.3 |
All amounts in ₹ Crores